Clinical efficacy of Eribulin new for metastatic breast cancer
Not Applicable
- Conditions
- progressive or metastatic breast cancer patients
- Registration Number
- JPRN-UMIN000014445
- Lead Sponsor
- Graduate School of Medicine and Faculty of Medicine, the University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who sustain adverse events using after taxanes. Patients who have not enough judgment ability minors, in adults, cases of acquisition agreement by the description document is difficult. Patients who are subjected to treatment without their doctors not revealing the breast cancer treatment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method OS,PFS
- Secondary Outcome Measures
Name Time Method ORR,TTF,adverse ebents